Veterinary cardiologist, Dr. Hayley McDonald Explains All about Felicyn CA-1
Hypertrophic cardiomyopathy (HCM) is the most common form of heart disease in cats, affecting an estimated 1 in 7 felines. This translates to approximately 15% of the cat population.
Felycin®-CA1 (sirolimus delayed-release tablets) is the first disease-modifying drug that can give hope to owners of cats with subclinical hypertrophic cardiomyopathy (HCM).Felycin®-CA1 is the first and only FDA conditionally approved once-weekly drug for the management of ventricular hypertrophy in cats with subclinical HCM. Read our detailer to learn more about Felycin-CA1.
Veterinary cardiologist, Dr. Hayley McDonald, explains all!
Disclosure statement: Through Vet Candy, Dr. Hayley McDonald received compensation for this video from PRN Pharmacal.
Share This Article
Free Membership
Enjoyed this article?
There's a lot more where that came from.
Join 50,000+ veterinary professionals who get free RACE-approved CE, weekly clinical updates, and the most talked-about veterinary magazine in the profession — all completely free.
Join Vet Candy Free →No credit card. No catch. Just everything veterinary.
